The Globe and Mail reports in its Thursday, July 20, edition that RBC Dominion Securities analyst Paul Quinn has elevated his recommendation for KP Tissue to "outperform" from "sector perform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Quinn gave his share target a $2 boost to $12. Analysts on average target the shares at $10.90. Mr. Quinn says in a note: "After a couple of years of being on the wrong side of increasing pulp prices, KP Tissue is now poised to benefit from materially lower input costs with the significant decline in prices since mid-2022 that has accelerated in 2023. Preliminary July list prices for NBSK and BEK are now 25 per cent and 33 per cent below peak levels reached in 2022. We think elevated inventory levels are likely to preclude a meaningful rally in pulp prices over the medium term. ... The company successfully implemented a strategy to manage pricing and costs over the last two years. As a result, we have raised our EBITDA financial forecasts for 2023 and 2024, up 9 per cent and 11 per cent." The Globe reported on March 14, 2022, that Mr. Quinn had downgraded KP Tissue to "sector perform" from "outperform." The shares could then be had for $10.61.